Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 30th June 2026
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.59% | - | -4.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 9.59% | - | -4.7% |
Mott Capital Management Thematic Growth Strategy declined 4.7% net in Q2 2026, underperforming the S&P 500's 10.2% total return, marking another quarter of underperformance largely tied to exuberance in semiconductor and AI-related stocks. While the strategy benefited from AI infrastructure focus in 2023-2024, the narrative shifted toward memory chips and semiconductors. Despite underperformance, underlying portfolio businesses continue performing well with strong year-over-year growth. Microsoft Azure and AWS continue growing over 40% and 35% respectively. The manager added Intuit, ServiceNow, and Cboe Global Markets during the quarter, high-quality SaaS businesses with pricing power not easily displaced by AI. Largest holdings Visa and Mastercard began performing well after a weak first half. The manager sold Boston Scientific after two consecutive weak quarters but maintains patience with fundamentally sound businesses. Cash declined to 10-15% as the manager deploys capital into forgotten quality stocks trading at reasonable valuations. While acknowledging S&P 500 overvaluation and high AI concentration risk, the manager believes many good stocks exist outside the AI frenzy and continues building positions for long-term growth.
The manager maintains conviction in a concentrated portfolio of high-quality growth companies with strong business fundamentals, despite recent underperformance driven by market exuberance in AI and semiconductor stocks, believing patient capital will be rewarded as the market eventually rotates back to fundamentally sound businesses trading at reasonable valuations.
The manager believes many investments are positioned in the right areas while some are simply out of favor, which can change quickly. If AI enthusiasm cools, capital could rotate back into current holdings. New additions to the portfolio should help revive upward momentum. While the S&P 500 and NASDAQ 100 may be overvalued with high concentration risk in AI and semiconductors, the manager does not believe the entire market is overvalued and sees many good stocks worth owning that have been forgotten due to AI focus.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Aug 10 2026 | 2026 Q2 | AMZN, BSX, CBOE, GOOGL, GRAL, ILMN, INTU, ISRG, MA, MSFT, NOW, V, ZTS | AI, Cloud, growth, payments, SaaS, semiconductors, technology, underperformance | - | Mott Capital underperformed in Q2 2026 as AI and semiconductor exuberance drove markets, but underlying portfolio businesses show strong fundamentals with cloud growth exceeding 35-40%. The manager added high-quality SaaS names like Intuit and ServiceNow while reducing cash to 10-15%, deploying into forgotten quality stocks. Despite near-term headwinds, conviction remains in patient capital being rewarded as markets eventually rotate from AI concentration. |
| May 11 2026 | 2026 Q1 | AMZN, BSX, GRAIL, INTU, MSFT, OXY, SHOP, UNH | AI, Biotechnology, energy, healthcare, oil, technology, volatility | - | Thematic growth strategy underperformed in volatile Q1 marked by healthcare earnings disappointments and oil price surge from geopolitical tensions. Manager maintains conviction in biotechnology innovation while tactically adjusting energy exposure. Initiated Intuit position at attractive valuations for AI exposure. Forward outlook cautious given narrow market leadership and uncertainty around central bank policy response to rising oil and inflation. |
| Feb 23 2026 | 2025 Q4 | AAPL, AMZN, BRK-A, BSX, GOOGL, GRAIL, META, MSFT, ORCL, OXY, ZTS | AI, Debt, energy, Rotation, technology, underperformance, valuation |
MSFT OXY |
Mott Capital underperformed in 2025 due to cautious AI stance amid bubble conditions. Manager reduced tech exposure, rotated into med-tech and energy sectors. Believes market's risk-on speculation will revert to traditional discipline. Positioned defensively for this transition while selectively investing in underperformed areas like energy through Occidental Petroleum. |
| Nov 10 2025 | 2025 Q3 | AMZN, GOOGL, GRAL, ILMN, MSFT, NVDA, UNH, ZTS | AI, Biotechnology, Capex, healthcare, large cap, technology | - | Kramer's thematic growth strategy underperformed in Q3 as he rotated away from AI-heavy mega-caps due to CapEx spending concerns. He trimmed Alphabet, added healthcare names like UnitedHealth and Grail, and maintains 25% cash. The defensive positioning reflects caution about AI spending sustainability while preserving flexibility to capitalize on emerging opportunities in sectors benefiting from AI differently. |
| Aug 8 2025 | 2025 Q2 | AAPL, BA, ISRG, MSFT, UNH, ZTS | Defensive, healthcare, Performance, technology, valuation, volatility |
MSFT UNH ZTS MSFT UNH ZTS |
Mott Capital's defensive positioning led to significant Q2 underperformance despite initial correctness during market downturns. Manager conflicted over Microsoft due to AI valuation concerns and potential commoditization risks. Selectively adding distressed opportunities like UnitedHealth while trimming China-exposed names. Expects volatility return in second half due to fiscal policy and tariff uncertainties. |
| May 5 2025 | 2025 Q1 | AAPL, AMZN, BA, ILMN, ISRG, MSFT, SHOP | China, earnings, Margins, Portfolio Management, tariffs, technology, Trade Policy, volatility | - | Kramer defensively repositioned his growth portfolio amid Trump tariff volatility, trimming Apple, Intuitive Surgical, and Microsoft to 5% weightings due to China exposure risks. The portfolio underperformed in Q1 (-6.46% vs S&P's -4.27%) but the manager believes markets underestimate ongoing trade policy impacts. Declining earnings estimates and margin compression concerns support his cautious stance. |
| Mar 2 2025 | 2024 Q4 | AMZN, ILMN, ISRG, MA, MSFT, NVDA, SHOP.TO | AI, Bubble, Cash, growth, risk, technology, Valuations | - | Mott Capital gained 17.85% in Q4 but lagged the S&P 500 due to avoiding Nvidia and AI stocks. Manager views current market as bubble-like with extreme valuations, holding 25% cash while waiting for better opportunities. Strong performers included Shopify, Intuitive Surgical, and Amazon, but overall positioning remains defensive given inflation risks and potential policy uncertainty. |
| Nov 2 2024 | 2024 Q3 | AAPL, AMZN, BA, GOOGL, ILMN, ISRG, MSFT, SHOP | AI, Cash, earnings, growth, technology, Valuations | BA | Mott Capital's Thematic Growth Portfolio underperformed in Q3 with 9.58% returns versus S&P 500's 22.1%. Manager maintains cautious stance on overvalued markets, holding 25-30% cash. Mixed stock performance with Illumina leading gains at 25% while Boeing declined 16.5%. Concerned about elevated S&P 500 margin estimates and unproven AI investment returns from major tech holdings. |
| Aug 1 2024 | 2024 Q2 | AAPL, AMZN, BA, CSCO, GILD, GOOGL, ILMN, ISRG, MA, MSFT, NVDA, SHOP, TSLA, V | Concentration, growth, healthcare, Mega Cap, technology, valuation | ILMN | Mott Capital underperformed in Q2 with a cautious stance amid bubble-like market conditions. The concentrated portfolio holds essential mega-cap tech names while maintaining 30% cash. Recent Illumina purchase reflects selective value hunting in AI-healthcare. Manager expects market transition as Fed cuts approach and volatility returns, favoring patient long-term positioning over momentum chasing. |
| May 8 2024 | 2024 Q1 | AAPL, ADBE, AMZN, BA, GOOGL, ISRG, MA, META, MSFT, NVDA, TSLA, V | AI, growth, inflation, large cap, rates, technology, Valuations | - | Mott Capital underperformed in Q1 with 2.8% returns versus S&P 500's 10.6%, maintaining defensive positioning amid dangerous AI momentum and high valuations. Manager holds elevated cash awaiting better entry points, concerned about Nvidia's market dominance, sticky inflation, and elevated rates. Core holdings include Microsoft, Amazon, and payment processors, positioned for aggressive deployment when valuations improve. |
| Jan 19 2024 | 2023 Q4 | AAPL, AMZN, BA, GOOGL, ISRG, MA, MDRX, MSFT, SHOP, SPLK, V | Cash, Fed, growth, rates, technology, Valuations | - | Mott Capital's thematic growth strategy returned 26.7% in 2023 through concentrated mega-cap holdings but maintains 35-40% cash amid valuation concerns. The manager sees stocks as expensive relative to bonds and believes markets are mispricing Fed rate cut expectations for 2024, creating potential downside risk requiring defensive positioning. |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2026 Q2 |
AIThe manager notes that AI-related stocks, particularly semiconductors and memory chips, drove S&P 500 gains in Q2. The strategy underperformed due to exuberance in AI stocks. The manager benefited from AI infrastructure focus in 2023-2024 but the narrative shifted. Microsoft, Alphabet, and Amazon continue heavy AI infrastructure spending with strong cloud growth. |
Semiconductors Memory Cloud Data Centers Infrastructure |
CloudMicrosoft Azure and Amazon Web Services continue exceptional growth, with Azure growing over 40% year-over-year and AWS growing over 35%. The hyperscalers are spending tremendous amounts to maintain and expand positions in AI infrastructure and data center markets while building out product suites. |
Azure AWS Data Centers Infrastructure | |
PaymentsVisa and Mastercard, the two largest holdings, have begun performing well after a weak first half. The manager views them as critical components of the global payment system powering e-commerce. Payments are becoming increasingly digital, and card-based purchases should continue growing well into the future, potentially enhanced by AI. |
Digital Payments E-commerce Credit Cards | |
SaaSThe manager bought Intuit and ServiceNow during the quarter, companies watched for years while waiting for opportunity. Both operate software-as-a-service models delivering high growth and strong margins. They are industry leaders with pricing power and are not easily displaced by AI integration. AI could support further growth through data feeds and efficiency tools. |
Enterprise Software Pricing Power Growth | |
GenomicsIllumina shares rose sharply after better-than-expected Q2 results and raised full-year outlook. Grail bounced back from Q1 decline as the market digests the path forward for Galleri cancer screening test. FDA will hold an adcom meeting in late September, which could open paths to approval and Medicare payments. |
Biotechnology Diagnostics FDA | |
Capital MarketsThe manager bought Cboe Global Markets, a leading options exchange operator in the United States. Options trading has expanded rapidly in recent years in US financial markets, and Cboe is the market leader. The manager believes options trading will continue to grow and play an increasingly important role in financial markets. |
Exchanges Options Trading | |
| 2026 Q1 |
OilWTI oil prices soared to over $100 per barrel due to the closure of the Strait of Hormuz from U.S.-Iran engagement. The manager reduced Occidental position from 8% to 5% to lock in gains given volatility. Oil supply and demand imbalances are expected to drive prices higher regardless of conflict resolution expectations. |
Oil Energy Occidental Geopolitical Volatility |
BiotechnologyGrail's cancer screening test failed to meet its endpoint for detecting stage 1 and 2 cancers but still detected more stage 3 cancers. The manager maintains strong conviction in the stock and underlying technology despite the setback, expecting potential rebound with additional data presentation. |
Biotechnology Cancer Screening Grail Healthcare | |
AIIntuit is positioned to benefit from advancements in AI over time. The manager initiated a position in Intuit after its stock declined significantly, viewing the valuation as more attractive. |
AI Software Intuit Technology Valuation | |
| 2025 Q4 |
AIManager believes AI sector is experiencing bubble-like conditions with excessive debt accumulation and unsustainable CAPEX spending. Software stocks have fallen sharply in 2026 as valuations come back to haunt them and fears of AI cannibalization rise. The manager's cautious approach in 2025 and continued cautious outlook are being validated by recent market sentiment shifts. |
Software Valuations Debt CAPEX Bubble |
EnergyManager purchased Occidental Petroleum at the start of 2026, believing oil prices are currently depressed and the energy sector has underperformed significantly. Oil appears to be the only commodity not performing well, and both Occidental and the energy sector haven't performed this poorly versus the S&P 500 since the dot-com bubble. |
Oil Commodities Underperformance Value | |
Med-techManager has been rotating into med-tech stocks to shift exposure into a group that hasn't performed as well as technology but still benefits from ongoing technological trends. Examples include acquisition of Grail and swapping Zoetis for Boston Scientific, though Boston Scientific has fallen sharply following disappointing earnings. |
Medical Devices Technology Rotation | |
| 2025 Q3 |
AIManager expresses concern about heavy AI spending by mega-cap companies, particularly their dramatically increased CapEx investments over the past couple of years. He fears the spending could become an ongoing, perhaps never-ending process given the immense and continually growing demands for computing power and energy to deploy AI tools, potentially weighing on overall cash flow. |
Artificial Intelligence CapEx Computing Power Energy |
| 2025 Q2 |
AIManager expresses genuine conflict about AI investments, particularly Microsoft, due to valuation concerns and uncertainty about returns on substantial data center spending. Questions whether AI sector will recoup considerable investments and fears AI risks becoming commoditized technology over time without clear differentiation among models. |
Data Centers Valuation Technology Investment Returns Commoditization |
| 2025 Q1 |
Trade PolicyPresident Trump's tariff plan created significant market volatility, with the market underestimating his determination to reshape global trade. The manager believes tariffs will remain above a 10% floor and may be weaponized against China's weakened economy to slow military expansion. |
Tariffs China Trade Geopolitical Policy |
AIMicrosoft may scale back its Artificial Intelligence spending according to media reports, with potential capital expenditure reductions in fiscal year 2026 that could disappoint markets despite better-than-feared results and solid guidance. |
Microsoft Capex Technology Cloud Investment | |
| 2024 Q4 |
AIManager is skeptical of AI-related stock valuations, comparing the current environment to the 2000 dot-com bubble. Questions whether AI growth expectations will materialize quickly enough to justify current pricing, particularly for Nvidia which trades at very high valuations. |
Nvidia Bubble Valuations Growth Technology |
E-commerceShopify was the top performer in the portfolio during Q4, surging over 30% after delivering better-than-expected quarterly results. The strong performance helped narrow the gap between the strategy's performance and the S&P 500. |
Shopify Growth Results Performance | |
| 2024 Q3 |
AITechnology companies including Apple, Alphabet, Microsoft, and Amazon have indicated plans to increase AI spending in 2025 to stay competitive. However, the payoff from these AI investments has not materialized yet, and the market has started examining AI spending more closely since mid-July. |
Artificial Intelligence Technology Spending Investment Competition |
EarningsS&P 500 earnings estimates are being revised downward for 2024 and 2025 due to overestimated gross margin estimates and the impact of a strong dollar on earnings. Margin estimates starting at 13.8% for 2025 appear historically high and unlikely to be achieved, potentially reducing expected growth rates. |
Estimates Margins Revisions Growth Valuations | |
| 2024 Q2 |
AIRapid advancements in AI applications will likely support healthcare companies making meaningful advances in formulary and product development. The market has seen significant rotation into mega-cap stocks primarily led by Nvidia, creating substantial divergences across the market. |
Healthcare Nvidia Technology |
BiotechnologyManager learned hard lessons from biotech investments in early 2014 when future growth was already priced in. Illumina was purchased as a blood diagnostics company with AI applications potential, and the portfolio received Grail shares developing early cancer detection technology. |
Diagnostics Cancer Grail Illumina | |
| 2024 Q1 |
AIThe market is being dangerously driven by an Artificial Intelligence momentum trade with Nvidia as the primary beneficiary. Many companies are spending heavily on AI but aren't necessarily seeing revenue benefits, while only a handful like Nvidia are actually profiting. The AI rally appears momentum-based and questionable for continuation. |
Nvidia Momentum Revenue Spending Chips |
InflationInflation remains sticky in the mid-3% range, which likely means rates will remain higher for an extended period. The velocity of money is rising as nominal GDP growth outpaces money supply growth, which creates inflationary pressure and keeps bond yields elevated. |
Sticky Rates Velocity GDP Yields | |
RatesInterest rates are at their highest levels in decades and likely to remain elevated. The risk-free rate around 4.5% creates challenging conditions for equity valuations, with bond yields potentially continuing to rise due to money velocity dynamics. |
Treasury Risk-free Elevated Yields Decades | |
| 2023 Q4 |
GrowthThe composite focuses on thematic growth investing with a long-term approach, owning mega-cap growth names like Apple, Microsoft, Alphabet, and Amazon. The strategy has benefited from the rally in mega-cap growth stocks in 2023. |
Mega Cap Technology Long Term Quality Thematic |
RatesInterest rates surged in 2023 with the 10-year Treasury climbing to around 4% from 3.7%. The market is betting on aggressive Fed rate cuts in 2024, but the manager believes the Fed will deliver fewer cuts than priced in. |
Fed Treasury Rate Cuts Monetary Policy | |
InflationThe portfolio owns Visa and Mastercard as inflation hedges since their fees rise as prices rise. The strategy considers inflation protection in positioning decisions. |
Hedging Payments Pricing Power |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Fund Letters | Michael J. Kramer | MSFT | Microsoft Corporation | Information Technology | Systems Software | Bear | NASDAQ | CapEx, debt, monetization, platform, Risk, Software, valuation | Login |
| Feb 23, 2026 | Fund Letters | Michael J. Kramer | OXY | Occidental Petroleum Corporation | Energy | Oil & Gas Exploration & Production | Bull | New York Stock Exchange | commodity, Cyclicality, energy, Float, Mean Reversion, oil, Ownership | Login |
| Aug 8, 2025 | Fund Letters | Michael J. Kramer | MSFT | Microsoft Corporation | Information Technology | Systems Software | Bear | NASDAQ | AI, CapEx, cloud, Competition, valuation | Login |
| Aug 8, 2025 | Fund Letters | Michael J. Kramer | UNH | UnitedHealth Group Inc. | Health Care | Managed Health Care | Bull | NASDAQ | healthcare, Insurance, scale, turnaround, valuation | Login |
| Aug 8, 2025 | Fund Letters | Michael J. Kramer | ZTS | Zoetis Inc. | Health Care | Pharmaceuticals | Bull | New York Stock Exchange | growth, Margins, Pets, pharmaceuticals, secular trends | Login |
| Aug 8, 2025 | Fund Letters | Mott Capital Management | MSFT | Microsoft Corporation | Information Technology | Systems Software | Neutral | NASDAQ | AI, capital expenditure, Cloud computing, Commoditization, data centers, Software, technology, valuation | Login |
| Aug 8, 2025 | Fund Letters | Mott Capital Management | UNH | UnitedHealth Group Incorporated | Health Care | Managed Health Care | Bull | NYSE | CEO change, contrarian, defensive, health insurance, healthcare, managed care, turnaround, Value | Login |
| Aug 8, 2025 | Fund Letters | Mott Capital Management | ZTS | Zoetis Inc. | Health Care | Pharmaceuticals | Bull | NYSE | Animal Health, Demographics, healthcare, Pet Ownership, pharmaceuticals, undervalued, Value, Veterinary | Login |
| Nov 2, 2024 | Fund Letters | Mott Capital Management | BA | The Boeing Company | Industrials | Aerospace & Defense | Bull | NYSE | Aerospace, Commercial Aviation, duopoly, Equity, Order Backlog, turnaround | Login |
| Aug 1, 2024 | Fund Letters | Mott Capital Management | ILMN | Illumina Inc | Health Care | Life Sciences Tools & Services | Bull | NASDAQ | AI applications, Biotech, Cancer Detection, diagnostics, Genomics, Healthcare Technology, life sciences, turnaround, Value Investment | Login |
| TICKER | COMMENTARY |
|---|---|
| MSFT | Microsoft, Alphabet, and Amazon are all spending tremendous amounts of money to maintain and expand their positions in AI infrastructure and data center markets. They also continue to build out their own suites of products. Microsoft Azure and Amazon Web Services continue to grow exceptionally well, with Azure growth at more than 40% year over year and AWS growth at more than 35%. |
| GOOGL | Microsoft, Alphabet, and Amazon are all spending tremendous amounts of money to maintain and expand their positions in AI infrastructure and data center markets. They also continue to build out their own suites of products. |
| AMZN | Microsoft, Alphabet, and Amazon are all spending tremendous amounts of money to maintain and expand their positions in AI infrastructure and data center markets. They also continue to build out their own suites of products. Microsoft Azure and Amazon Web Services continue to grow exceptionally well, with Azure growth at more than 40% year over year and AWS growth at more than 35%. |
| ILMN | Illumina shares rose sharply after the company reported better-than-expected second-quarter results and raised its full-year outlook. |
| ISRG | Intuitive Surgical shares fell sharply after the company reported solid results but issued softer-than-expected procedure-growth guidance. |
| GRAL | Grail has bounced back from its sharp decline in the first quarter, as the market begins to digest the path forward for Galleri, the company's cancer screening test. Additionally, it recently announced that the FDA will hold an adcom meeting for the test in late September. If the meeting goes well and the panel votes in favor of Galleri, it could open a path to not only FDA approval but potential entry for Medicare payments, which would be a big win for the company. |
| V | Additionally, our two largest holdings, Visa and Mastercard, have finally begun to perform well after a weak first half of the year. I continue to believe that these two companies are critical components of the global payment system and help power e-commerce. Regardless of trends in AI, I believe they will remain valuable and important in the future. Payments are becoming increasingly digital, and purchases made using debit and credit cards should continue to grow well into the future; AI may only help enhance that as more transactions move away from traditional methods. |
| MA | Additionally, our two largest holdings, Visa and Mastercard, have finally begun to perform well after a weak first half of the year. I continue to believe that these two companies are critical components of the global payment system and help power e-commerce. Regardless of trends in AI, I believe they will remain valuable and important in the future. Payments are becoming increasingly digital, and purchases made using debit and credit cards should continue to grow well into the future; AI may only help enhance that as more transactions move away from traditional methods. |
| INTU | During the quarter, I bought shares of Intuit, ServiceNow, and Cboe Global Markets for the strategy. These are companies I have watched for years while waiting for an opportunity to buy them because they have strong businesses and play integral roles in their industries. Intuit and ServiceNow operate software-as-a-service business models that deliver high growth rates and strong margins. Both are industry leaders with pricing power and, in my view, are not easily displaced by integration of AI. If implemented effectively, I also believe AI could support further growth, as customers may pay for access to data feeds and tools that improve information flow and efficiency. |
| NOW | During the quarter, I bought shares of Intuit, ServiceNow, and Cboe Global Markets for the strategy. These are companies I have watched for years while waiting for an opportunity to buy them because they have strong businesses and play integral roles in their industries. Intuit and ServiceNow operate software-as-a-service business models that deliver high growth rates and strong margins. Both are industry leaders with pricing power and, in my view, are not easily displaced by integration of AI. If implemented effectively, I also believe AI could support further growth, as customers may pay for access to data feeds and tools that improve information flow and efficiency. |
| CBOE | During the quarter, I bought shares of Intuit, ServiceNow, and Cboe Global Markets for the strategy. These are companies I have watched for years while waiting for an opportunity to buy them because they have strong businesses and play integral roles in their industries. Cboe Global Markets is a leading options exchange operator in the United States. Options trading has expanded rapidly in recent years in US financial markets, and Cboe is the leader in the market. I believe options trading will continue to grow and play an increasingly important role in financial markets. |
| ZTS | Overall, when an investment thesis does not work—as was the case with Zoetis in late 2025 and Boston Scientific in 2026—and the stock price is falling while the business appears to be struggling, it makes sense to sell and move on. |
| BSX | In the case of Boston Scientific, we sold this stock this quarter after the company reported its second weak quarter in a row. One weak quarter can happen to any company, but two consecutive weak quarters can change the investment thesis. At that point, it is often best to cut one's losses and move on. Unfortunately, those losses hurt near-term performance. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||